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pRb is required for MEF2-dependent gene expression as well as
cell-cycle arrest during skeletal muscle differentiation
Bennett G. Novitch*†, Douglas B. Spicer*‡, Paul S. Kim, Wang L. Cheung
and Andrew B. Lassar
Background: The onset of differentiation-specific gene expression in skeletal
muscle is coupled to permanent withdrawal from the cell cycle. The
retinoblastoma tumor-suppressor protein (pRb) is a critical regulator of this
process, required for both cell-cycle arrest in G0 phase and high-level
expression of late muscle-differentiation markers. Although the cell-cycle defects
that are seen in pRb-deficient myocytes can be explained by the well-described
function of pRb as a negative regulator of the transition from G1 to S phase, it
remains unclear how pRb positively affects late muscle-gene expression.
Results: Here, we show that the myogenic defect in Rb–/– cells corresponds to
a deficiency in the activity of the transcription factor MEF2. Without pRb, MyoD
induces the accumulation of nuclear-localized MEF2 that is competent to bind
DNA yet transcriptionally inert. When pRb is present, MyoD stimulates the
function of the MEF2C transcriptional activation domain and the activity of
endogenous MEF2-type factors. Co-transfection of MyoD together with an
activated form of MEF2C containing the Herpesvirus VP16 transcriptional
activation domain partially bypasses the requirement for pRb and induces late
muscle-gene expression in replicating cells. This ectopic myogenesis is
nevertheless significantly augmented by co-expression of an E2F1–pRb
chimeric protein that blocks the cell cycle.
Conclusion: These findings indicate that pRb promotes the expression of late-
stage muscle-differentiation markers by both inhibiting cell-cycle progression and
cooperating with MyoD to promote the transcriptional activation activity of MEF2.
Background
Skeletal muscle differentiation (myogenesis) involves a
cascade of muscle-specific gene expression that is coordi-
nated with permanent withdrawal from the cell cycle. The
commitment of cells to the myogenic lineage requires either
of two members of the myogenic basic helix–loop–helix
(bHLH) transcription-factor family, MyoD or Myf-5, which
are expressed in proliferating myoblasts prior to the onset of
muscle differentiation (reviewed in [1–3]). Further steps in
myogenesis require another myogenic bHLH factor, myo-
genin, as well as the MEF2 transcription-factor family
which cooperate with the myogenic bHLH proteins in the
activation of many muscle structural genes (reviewed in
[1–3]). Studies of the differentiation of cultured myoblasts
have revealed that muscle-differentiation-specific gene
expression occurs in a stereotypic pattern. Within 24 hours
of serum removal, proliferating myoblasts initiate the
expression of myogenin. Subsequently, these cells express
the cyclin-dependent kinase (Cdk) inhibitor p21 and per-
manently exit the cell cycle. Once the cells have become
post-mitotic, expression of myofibrillar proteins such as
myosin heavy chain (MHC) and enzymatic genes such as
muscle creatine kinase (MCK) begins, approximately
36–48 hours after the onset of differentiation, followed by
fusion of cells into multinucleated myotubes [4–6].
With the exception of the earliest induction of myogenin,
and perhaps p21, muscle-differentiation-specific transcrip-
tion occurs exclusively in non-dividing cells, suggesting
that the expression of most differentiation-specific genes
requires an arrest in the G0 phase of the cell cycle. This
idea is supported by findings that muscle-gene expression
can be inhibited by peptide growth factors, activated
oncogenes, or other proteins that promote cell-cycle pro-
gression (reviewed in [6–9]). Most of these studies indi-
cate that perturbation of the cell cycle antagonizes the
function of the myogenic bHLH proteins, resulting in a
general absence of differentiation-specific gene expres-
sion in dividing cells. However, these studies have not
clarified why early markers of the myogenic program, such
as myogenin, can be expressed in proliferating cells
whereas late markers of the differentiation program are
induced only after cell-cycle withdrawal.
The retinoblastoma tumor-suppressor protein (pRb) plays
a critical role in establishing the G0 arrest observed in 
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differentiated myocytes; muscle cells lacking pRb fail to
exit the cell cycle and are susceptible to apoptotic cell death
[10–13]. In addition, pRb is required for certain aspects of
the muscle differentiation program. Whereas pRb-deficient
muscle cell lines express normal levels of both myogenin
and p21, these cells express reduced levels of MHC and are
unable to activate the expression of a transfected MCK
reporter construct [10]. These in vitro findings parallel the
muscle defects observed in mice that express reduced
levels of pRb during embryogenesis. Skeletal muscle in
these animals contains wild-type levels of the early muscle-
differentiation markers myogenin and cardiac α-actin, but
diminished levels of the late muscle-differentiation markers
MCK and MRF4 [12]. Furthermore, fusion of pRb-defi-
cient myocytes into multinucleated myotubes is markedly
impaired [12]. Thus, pRb is specifically required for execu-
tion of the later steps in skeletal myogenesis, and its
absence molecularly uncouples the early and late phases of
this differentiation program.
It is currently believed that pRb controls cell-cycle progres-
sion through its ability to silence E2F-dependent genes
(reviewed in [14]), but it is unclear whether this or a differ-
ent property of pRb stimulates late muscle-gene expres-
sion, as pRb mutants that fail to bind stably to E2F can still
enhance muscle differentiation [15]. To better understand
the mechanism(s) through which pRb positively affects
myogenesis and to ascertain why the later steps of myogen-
esis are specifically altered in the absence of pRb, we have
further characterized the differentiation defects that are
seen in pRb-deficient muscle cells. We demonstrate that
the failure to activate late muscle-gene expression in pRb-
deficient myocytes is due to a requirement for both MyoD
and pRb in the activation of MEF2 transactivation-domain
(TAD) function. The need for pRb and cell-cycle exit in
the later stages of myogenesis can be partially fulfilled by
artificially activating MEF2. Full restoration of the muscle-
differentiation program in Rb–/– cells, however, requires
both MEF2 activation and cell-cycle arrest. Together,
these findings indicate that pRb regulates the later stages
of myogenesis through its ability both to arrest cellular
growth and, in conjunction with MyoD, to affect MEF2
function positively. Because MyoD and pRb are both
required to functionally activate MEF2, our findings
further suggest that modulation of pRb function may act to
restrict the expression of MEF2-dependent late muscle-
differentiation markers to post-mitotic cells.
Results
pRb is required for MEF2 activation during skeletal muscle
differentiation
Previous observations that early muscle differentiation
markers are normally expressed in the absence of pRb have
suggested that the ability of MyoD to activate transcription
per se might be pRb-independent. The specific loss of late
muscle-specific gene expression in pRb-deficient myocytes
might then result from the reduced function of another
pRb-dependent component of the myogenic program. To
test this possibility, we first determined whether MyoD
required pRb to activate a simplified reporter construct
containing four repeated MyoD-binding sites (E-box
reporter). In Rb–/– fibroblasts, MyoD significantly activated
this reporter, and co-expression of pRb only slightly
enhanced this activity (Figure 1a, compare columns 2
and 3). A similar result was obtained with a p21 promoter
construct that also contains multiple E-box elements (data
450 Current Biology, Vol 9 No 9
Figure 1
Activation of endogenous MEF2 function by
MyoD requires pRb. (a) Rb–/– fibroblasts were
transiently transfected with a CAT reporter
construct containing four repeated MyoD-
binding sites (E-box reporter) along with
expression plasmids for MyoD, the bHLH
domain of MyoD fused to the herpesvirus
VP16 transcriptional-activation domain
(MyoD–VP16), and pRb, as indicated (+).
(b) Rb–/– fibroblasts were transfected with a
CAT reporter construct containing four
repeated MEF2-binding sites (MEF2 reporter)
along with expression plasmids for MyoD,
MyoD–VP16, full-length MEF2C, the MADS
and MEF2 domain of MEF2C fused to VP16
(MEF2C–VP16), and pRb, as indicated. Error
bars represent the results from duplicate
plates from a representative experiment.
MyoD:
MyoD–VP16:
pRb:
(a)
0
10
20
30
40
50
60
1 2 3 4 5
R
el
at
iv
e 
ac
tiv
ity
R
el
at
iv
e 
ac
tiv
ity
+ +
+
+ +
+
E-box reporter
1 2 3 4 5 6 7 8 9
+ +
+
+
+ +
+
+
+
+ +
+
(b)
MEF2 reporter
MyoD:
MyoD–VP16:
MEF2C:
MEF2C–VP16:
pRb:
   Current Biology
0
4
8
12
16
20
48
52
56
not shown). These experiments indicate that, although co-
transfected pRb can increase E-box reporter activity,
MyoD substantially activates transcription in its absence.
As muscle differentiation proceeds, myogenic bHLH pro-
teins induce the expression and activity of members of
the MEF2 transcription factor family [16,17], which are
thought to be important for the expression of a number of
skeletal muscle-specific genes (reviewed in [1–3,18]).
Furthermore, in Drosophila, D-MEF2-deficient embryos
contain myoblasts that fail to undergo the later phases of
muscle differentiation [19–21], similar to the muscle phe-
notype of Rb–/– mice. We therefore thought that pRb
could be required for MyoD either to induce the expres-
sion of MEF2 or perhaps to affect the DNA-binding or
transcriptional-activation properties of the MEF2 proteins
themselves. To test these possibilities, we transfected
Rb–/– fibroblasts with a MyoD expression plasmid and
assayed whether endogenous MEF2 activity was
increased by monitoring the activity of a MEF2 reporter
construct containing four repeated MEF2-binding sites
(MEF2 reporter), in either the absence or the presence of
pRb. As previously observed with the activation of the
MCK promoter ([10], see also below), MyoD required
pRb to activate the MEF2 reporter (Figure 1b, columns 2
and 3). Strikingly, activation of the MEF2 reporter by a
fusion protein consisting of MyoD with the herpesvirus
VP16 transactivation domain (MyoD–VP16) remained
predominantly pRb-dependent (Figure 1b, columns 4
and 5), even though MyoD–VP16 alone activated the
E-box reporter considerably more than did wild-type
MyoD and pRb together (Figure 1a, columns 3 and 4).
Moreover, MyoD–VP16 did not activate the MEF2
reporter to significantly greater levels in either the
absence or the presence of pRb than did wild-type MyoD
(Figure 1b, compare columns 2 and 3 with columns 4
and 5). Together, these findings indicate that pRb is
specifically required for MyoD-mediated activation of
MEF2 and that this process is not a direct function of the
transactivation abilities of MyoD. 
MEF2 expression, DNA binding, and nuclear localization
are not modulated by pRb
To discern the step in the regulation of MEF2 activity at
which Rb–/– myocytes were blocked, we investigated
whether MEF2 expression levels, DNA-binding proper-
ties, or nuclear localization were modulated in a MyoD-
dependent and/or pRb-dependent manner. As reported
previously [10], pRb-deficient fibroblasts infected with a
MyoD retrovirus express wild-type levels of myogenin
upon differentiation, but they express markedly reduced
levels of MHC and MCK (Figure 2a, compare lanes 2 and
4). Interestingly, whereas MCK was only slightly induced
by MyoD in the absence of pRb, the brain isoform of crea-
tine kinase (BCK) was highly upregulated (Figure 2a, lane
2). BCK is normally expressed at low levels in proliferating
myoblasts and, like myogenin and p21, is upregulated
within the first 24 hours of myogenic differentiation. As
differentiation proceeds, however, its expression normally
declines as it is replaced by the muscle-specific isoform,
MCK [22]. Together, the elevated expression of BCK and
decreased expression of both MHC and MCK are evidence
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Figure 2
MyoD induces nuclear-localized MEF2 protein that can bind DNA in
the absence of pRb. (a,b) Protein extracts were prepared from Rb–/– or
wild-type fibroblasts infected with a retrovirus encoding MyoD, as
indicated, and then allowed to differentiate for 3 days. (a) Western
analysis of muscle-specific protein expression. The more slowly
migrating brain isoform (B) and the faster-migrating muscle isoform (M)
of creatine kinase are indicated. When normalized to MyoD content,
the levels of muscle-protein expression in Rb–/– cells relative to wild-
type determined by scanning densitometry were: myogenin, 75%;
MEF2, 110%; MHC, 9%; BCK, 2000%; MCK, 1%. (b) MyoD induces
MEF2 DNA-binding complexes in either the absence or presence of
pRb. Electrophoretic mobility shift assay (EMSA) analysis of E-box and
MEF2 DNA-binding activities. Complexes of MyoD and its E-protein
binding partner (MyoD–E protein), myogenin–E protein, and MEF2,
with DNA are indicated. (c–n) MyoD induces nuclear accumulation of
MEF2 in either the absence or presence of pRb. Rb–/– fibroblasts were
transiently transfected with expression vectors encoding either
(c–e) β-galactosidase, (f–h) Myc-tagged MyoD, (i–k) pRb, or (l–n) the
combination of MyoD and pRb. Cells were immunostained for (c,f,i) the
transfected protein, (l) transfected MyoD, and (d,g,j,m) endogenous
MEF2. (e,h,k,n) Nuclei were visualized by DAPI staining.
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of a specific blockade in the expression of late differentia-
tion markers in MyoD-infected Rb–/– cells.
Although these pRb-deficient myocytes failed to fully dif-
ferentiate, MyoD induced MEF2 protein expression to
wild-type levels (Figure 2a, compare lanes 2 and 4). Elec-
trophoretic mobility shift assays (EMSA) revealed that
MyoD also induced identical amounts of MEF2 DNA-
binding activity in either the absence or the presence of
pRb (Figure 2b), indicating that the observed defects in
MEF2 function were not due to impaired DNA binding.
Recently, it has been demonstrated that MEF2 proteins
can be regulated by translocation to the cytoplasm [23].
We therefore investigated whether the localization of
MEF2 was affected by pRb, and found that MyoD
induced similar levels of nuclear MEF2 accumulation
whether or not pRb was co-expressed (compare Figure 2g
with 2m). These findings indicate that neither the protein
levels, nor the DNA-binding properties, nor the nuclear
localization of MEF2, is abnormal in Rb–/– fibroblasts that
express MyoD, and suggest that the inability of MyoD to
induce MEF2-reporter activity reflects a deficiency in
some other aspect of MEF2 function.
A MEF2–VP16 chimera provides MEF2 function in the
absence of both MyoD and pRb
Because fibroblasts express very low levels of MEF2
protein in the absence of MyoD (Figure 2a), we investi-
gated whether pRb affected the activity of exogenously
supplied MEF2. When transfected into Rb–/– cells,
MEF2C activated the MEF2 reporter poorly, even when
pRb was co-expressed (Figure 1b, columns 6,7), suggest-
ing that exogenously expressed MEF2 also requires addi-
tional factors or modifications to reveal its functional
capacity. The effects seen here were not unique to
MEF2C, as we obtained similar results with transfected
MEF2A and MEF2D (data not shown). These findings
indicate that both MyoD and pRb together are required to
enhance MEF2 function.
To see whether the induction of MEF2 activity was a
property of the MEF2 TAD, we tested whether a
chimeric protein containing the MEF2C DNA-binding
domain (amino acids 1–117) linked to the VP16 TAD
(MEF2C–VP16 [24]) required either MyoD or pRb for its
function. We found that MEF2C–VP16 was a potent acti-
vator of the MEF2 reporter in the absence of MyoD, and
that the activity of this construct was not significantly aug-
mented by the co-expression of pRb (Figure 1b, compare
columns 8 and 9). Similar results were obtained with a
construct consisting of the VP16 TAD fused to full-length
MEF2C (data not shown). Together, these findings
demonstrate that MyoD-mediated induction of MEF2
function is specifically defective in pRb-deficient cells,
and that the transcriptional activity of MEF2 can be
restored by appending the VP16 TAD to MEF2.
MyoD stimulates the activity of the MEF2C transactivation
domain 
Given that fusing a VP16 TAD onto MEF2C activated
MEF2C in the absence of both MyoD and pRb, we rea-
soned that the myogenic defect in pRb-deficient fibrob-
lasts could result from a failure of MyoD to positively affect
the function of the wild-type MEF2C TAD. To explore
this possibility, we co-transfected pRb-positive 10T½
fibroblasts with an expression vector encoding a chimeric
protein consisting of the yeast Gal4 DNA-binding domain
fused to the TAD of human MEF2C (see Figure 3a [25]),
in either the absence or the presence of expression vectors
encoding MyoD and its E-protein binding partner, E12.
Gal4–MEF2C alone weakly activated a co-transfected
Gal4-reporter construct, but the inclusion of MyoD and
E12 increased this activity at least 10-fold (Figure 3b,
compare columns 3 and 4). In 10T½ cells, activation of
MEF2 reporter constructs was maximally enhanced by the
co-expression of MyoD with E12 (data not shown); we
therefore included exogenous E12 in this and in subse-
quent experiments. Importantly, the expression of E12 by
itself did not enhance Gal4–MEF2C activity (data not
shown), indicating that MyoD was required to activate the
MEF2C TAD. Furthermore, transfection of MyoD and
E12 in the absence of Gal4–MEF2C failed to activate the
Gal4 reporter (Figure 3b, column 2). Moreover, co-transfec-
tion with MyoD and E12 did not significantly augment the
activity of a Gal4–VP16 TAD chimera (data not shown),
indicating that MyoD and E12 expression specifically
induces the function of the MEF2C TAD. It has been
shown previously that MyoD and MEF2 are able to inter-
act directly  through their bHLH and MADS/MEF2
domains, respectively [24,26]. Since the Gal4–MEF2 con-
struct that we employed lacks the MADS/MEF2 domain
[25], these data further suggest that MyoD can modulate
MEF2 function in the absence of a direct interaction.
pRb promotes MyoD-mediated activation of the MEF2C
transactivation domain 
To test whether pRb is required for MyoD to activate the
MEF2C TAD, we transfected Rb–/– fibroblasts with the
Gal4–MEF2C fusion protein either alone or with MyoD and
E12, in either the absence or the presence of exogenous
pRb. When expressed alone, MyoD+E12 did not signifi-
cantly stimulate Gal4–MEF2C function in these cells
(Figure 3c, column 4). Similarly, the expression of pRb alone
did not affect the activity of Gal4–MEF2C (Figure 3c,
column 5); but, the combined expression of MyoD+E12 and
pRb led to a 45-fold increase in the activity of Gal4–MEF2C
(Figure 3c, column 6). These findings indicate that MyoD-
mediated activation of the MEF2C TAD requires pRb.
MyoD-mediated activation of the MEF2C transactivation
domain requires Ser387 of MEF2C
Recently, it was reported by Han et al. [25] that the 
TAD of MEF2C can be positively regulated through 
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phosphorylation by members of the p38 mitogen-activated
protein (MAP) kinase family at three residues within
MEF2C: Thr293, Thr300, and Ser387 (Figure 3a). In
monocytic cells, mutation of these residues to alanine 
prevents MEF2C activation in response to either
lipopolysaccharide stimulation or constitutive activation of
the p38 kinase pathway [25]. Because these residues are
required for enhanced MEF2C activity in monocytic cells,
we tested whether MyoD activation of Gal4–MEF2C
required the same amino acids. The combined mutation of
both Thr293 and Thr300 to alanine (T293;300A) did not
affect the basal activity of Gal4–MEF2C (Figure 3b,
compare columns 3 and 5), but did enhance the activity of
Gal4–MEF2C when MyoD+E12 were co-expressed
(Figure 3b, compare columns 4 and 6). In contrast, mutation
of Ser387 to alanine (S387A) decreased the basal activity of
Gal4–MEF2C and completely eliminated its activation by
co-transfected MyoD+E12 (Figure 3b, columns 7,8).
Importantly, activation of the p38 kinase pathway did stim-
ulate the function of the S387A Gal4–MEF2C mutant (data
not shown; see also [25,27]), indicating that this mutation
does not simply inactivate the protein. Therefore, MyoD
activation of the MEF2C TAD requires Ser387, but neither
Thr293 nor Thr300, of MEF2C.
Expression of MyoD together with MEF2C–VP16
dissociates activation of the MCK promoter from G0 arrest
Given that MyoD-mediated activation of the MEF2 TAD
required pRb, we evaluated whether artificial activation of
MEF2 could bypass the requirement for pRb for late
muscle-gene expression. We therefore tested whether
MEF2C–VP16 could cooperate with MyoD in the activa-
tion of an MCK–luciferase reporter construct in Rb–/–
fibroblasts. The combination of MyoD+E12 and
MEF2–VP16 induced MCK–luciferase expression to
levels significantly above that obtained with MyoD+E12
alone, to 30% of that observed with MyoD+E12 and pRb
(Figure 4a, compare columns 2,3,5). In marked contrast,
the combination of MyoD+E12 and wild-type MEF2C
failed to induce MCK–luciferase expression in the
absence of pRb (Figure 4a, column 4). Activation of the
MCK–luciferase reporter required MyoD, as expression of
MEF2C–VP16 alone did not activate it (data not shown).
Interestingly, the addition of the VP16 TAD activated
MCK–luciferase expression only when appended to
MEF2; the combination of MyoD–VP16+E12 and wild-
type MEF2C failed to drive expression of this reporter
construct (data not shown).
Because co-expression of MyoD with MEF2C–VP16 sub-
stantially activated the MCK promoter in the absence of
pRb, we examined whether this induction of differentia-
tion-specific gene expression coincided with cell-cycle
exit. To evaluate this, we transfected pRb-deficient
fibroblasts with MyoD and an MCK–CAT reporter con-
struct along with either pRb or MEF2C–VP16. After
allowing the cells to differentiate under low serum condi-
tions, we added mitogen-rich medium containing the
thymidine analog bromodeoxyuridine (BrdU) and evalu-
ated the frequency of BrdU uptake in MCK–CAT-positive
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Figure 3
MyoD requires pRb to activate the MEF2C transactivation domain.
(a) The Gal4–MEF2C mutants used in the subsequent panels.
Gal4–MEF2C (T293;300A) contains two threonine residues within the
MEF2C transactivation domain that have been substituted with alanine;
Gal4–MEF2C (S387A) has a single serine-to-alanine change.
(b) Rb-positive 10T½ fibroblasts were transfected with a reporter
construct containing five Gal4-binding sites upstream of luciferase
either in the absence or the presence of MyoD and E12 plus the
following Gal4–MEF2C fusion proteins, as indicated: Gal4–MEF2C
(WT), Gal4–MEF2C (T293;300A); Gal4–MEF2C (S387A). Reporter
activity relative to that observed with empty plasmid vectors (column 1)
is displayed. Error bars represent duplicate plates from a representative
experiment. (c) The Gal4–luciferase reporter was transfected into Rb–/–
fibroblasts either in the absence or the presence of Gal4–MEF2C (WT)
plus empty vectors, MyoD and E12, and pRb, as indicated.
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cells. MyoD expression alone did not arrest the growth of
pRb-deficient cells or induce significant levels of CAT
expression (data not shown), consistent with an inability of
the MCK promoter to be activated in cycling cells. In con-
trast, co-expression of MyoD with pRb produced numer-
ous cells with strong CAT staining and a complete lack of
BrdU incorporation (Figure 4b–d). When the same analy-
sis was applied to cells co-transfected with MyoD and
MEF2C–VP16, we found many CAT-positive cells in the
culture. The intensity of CAT staining in these cells was
generally weaker than in those expressing pRb, however,
and strikingly, the majority of the MCK–CAT-positive
cells had incorporated BrdU (Figure 4e–g). By combining
MyoD with an activated form of MEF2, therefore, we
were  able to dissociate activation of the MCK promoter
from permanent cell-cycle exit in pRb-deficient cells. We
did, nevertheless, find a considerable number of cells in
the culture transfected with the combination of MyoD and
MEF2C–VP16 that contained high amounts of CAT stain-
ing and no BrdU incorporation (data not shown). This
finding suggested that, although cells could initiate the
later stages of muscle differentiation when MyoD was co-
expressed with MEF2C–VP16, a cell-cycle arrest might
still be necessary to achieve the highest levels of muscle-
gene expression.
The myogenic functions of pRb can be mimicked by a
combination of MEF2 activation and cell-cycle arrest
Given that pRb can both inhibit proliferation and support
the expression of muscle-differentiation-specific genes,
we reasoned that MEF2C–VP16 might be less effective
than pRb in promoting muscle differentiation because
MEF2–VP16 cannot stop the cell cycle. To investigate
whether blocking the cell cycle could augment myogene-
sis, we co-transfected pRb-deficient cells with the combi-
nation of MyoD+E12 and E2F1–pRb(SP), a chimeric
protein consisting of the DNA-binding domain from the
transcription factor E2F1 (amino acids 1–368) fused to the
‘small pocket’ (SP) domain of pRb (amino acids 379–792)
[28]. The pRb(SP) domain exhibits potent transcriptional
silencing activity when fused to DNA-binding proteins,
but does not stimulate myogenesis on its own ([28] and
data not shown). This E2F1–pRb(SP) chimera has previ-
ously been shown to mimic the anti-proliferative functions
of pRb by binding to E2F promoter sites and repressing
the expression of E2F-responsive genes [28]; yet it fails to
fully substitute for pRb in the activation of differentiation
programs [15]. Here, the co-expression of MyoD+E12
with E2F1–pRb(SP) increased MCK-promoter activity to
30% of that achieved following co-expression of
MyoD+E12 with pRb (Figure 4a, column 6; Figure 4h),
454 Current Biology, Vol 9 No 9
Figure 4
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High-level expression of an MCK reporter gene requires both activation
of MEF2 and cell-cycle arrest. (a) Rb–/– fibroblasts were transfected
with an MCK–luciferase reporter construct and either empty plasmid
vectors only (column 1), or expression vectors encoding MyoD and
E12 plus either pRb, MEF2C (WT), MEF2C–VP16, E2F1–pRb(SP), or
the combination of MEF2C–VP16 and E2F1–pRb(SP), as indicated.
Cells were allowed to differentiate for 2 days and subsequently
assayed for luciferase activity. (b–m) Rb–/– fibroblasts were
transfected with an MCK–CAT reporter construct and MyoD plus
either (b–d) pRb, (e–g) MEF2C–VP16, (h–j) E2F1–pRb(SP), or
(k–m) the combination of MEF2C–VP16 and E2F1–pRb(SP). After
differentiation, cells were stimulated with serum-rich medium
containing BrdU for 24 h. Cells were subsequently fixed and
immunostained for (b,e,h,k) CAT expression (green) and (c,f,i,l) BrdU
incorporation (red). (d,g,j,m) Nuclei were visualized by DAPI staining
(blue). The proportion of MCK–CAT-positive cells containing BrdU
staining is displayed as a percentage in the right-hand column and was
derived from three independent experiments. The total number of
MCK–CAT-positive cells counted for each condition were: pRb, 1006;
MEF2–VP16, 396; E2F1–pRb(SP), 134; and MEF2–VP16 +
E2F1–pRb(SP), 475. In (b–m), nuclei in MCK–CAT-expressing cells
are indicated by arrowheads.
even though this fusion protein efficiently prevented
BrdU uptake in MCK–CAT-positive cells (Figure 4h–j).
As E2F1–pRb(SP) retained the anti-proliferative property
of pRb but did not fully activate myogenesis on its own,
we tested whether it could cooperate with MEF2C–VP16
in our myogenesis assays. The combination of
MyoD+E12, MEF2C–VP16, and E2F1–pRb(SP) acti-
vated MCK–luciferase expression to a level equal to or
greater than that achieved following co-transfection of
MyoD+E12 with pRb (Figure 4a, compare columns 3 and
7), and led to the appearance of numerous cells in the
culture that displayed very high levels of CAT staining
and no BrdU incorporation (Figure 4k–m), very similar to
what was observed following transfection of MyoD with
pRb (Figure 4b–d). Cotransfection of E2F1–pRb(SP) and
MEF2C–VP16 in the absence of MyoD did not induce
the expression of MCK–CAT (data not shown). Thus, we
were able to fully substitute for the loss of pRb by co-
transfecting MyoD with an activated form of MEF2 and
the cell-cycle-arresting molecule E2F1–pRb(SP).
Because our results indicated that the combination of
MEF2C–VP16 and E2F1–pRb(SP) could support the
activity of MCK-reporter constructs as efficiently as could
pRb, we further evaluated the ability of these two proteins
to synergistically activate the expression of endogenous
muscle genes. In pRb-deficient fibroblasts, MyoD trans-
fection by itself induced low amounts of MHC expression
and little or no detectable MCK (Figure 5a–c). In contrast,
cells transfected with both MyoD and pRb produced high
levels of MHC and MCK (Figure 5d–f). Cotransfection of
MyoD with either MEF2C–VP16 or E2F1–pRb(SP) alone
led to a relatively small increase in the intensity of MHC
staining and low amounts of endogenous MCK expression
(Figure 5g–l). However, the combination of MyoD,
MEF2C–VP16, and E2F1–pRb(SP) produced cells that
expressed very high levels of both MHC and MCK
(Figure 5m–o), again mimicking the phenotype of cells
transfected with MyoD and pRb. In summary, these
results indicate that the ability of pRb to promote muscle
differentiation can be fully substituted by the combina-
tion of E2F1–pRb(SP) and MEF2C–VP16, suggesting
that the requirement for pRb to promote expression of
late muscle-differentiation markers reflects the ability of
this molecule both to arrest cells in G0 and to potentiate
MyoD-mediated activation of the MEF2 TAD.
Discussion
Suppression of cell-cycle progression and activation of
MEF2 synergistically activate myogenesis
In this study, we have determined that the block in terminal
muscle differentiation observed in Rb–/– cells corresponds to
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Figure 5
High-level expression of endogenous muscle
genes requires both activation of MEF2 and
cell-cycle arrest. Rb–/– fibroblasts were
transfected with MyoD plus either
(a–c) empty expression vector, (d–f) pRb,
(g–i) MEF2C–VP16, (j–l) E2F1–pRb(SP),
or (m–o) the combination of MEF2C–VP16
plus E2F1–pRb(SP). After 2 days under
differentiation conditions, cells were fixed
and immunostained for expression of
(a,d,g,j,m) myosin heavy chain (MHC; green)
and (b,e,h,k,n) muscle creatine kinase (MCK;
red). (c,f,i,l,o) Nuclei were visualized by DAPI
staining (blue). At least 300 myosin-positive
cells were evaluated for co-expression of
MCK in each panel. Representative fields
are shown.
MHC MCK DAPI
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an inability of MyoD to activate MEF2 function. When
pRb is absent, MyoD induces normal levels of nuclear-
localized MEF2 protein that is fully competent to bind
DNA yet transcriptionally inert. Activation of MEF2 func-
tion requires both MyoD and pRb and correlates with the
induction of the transactivation properties of the MEF2C
TAD. The requirement for pRb to promote muscle-gene
expression can be partially bypassed by co-expressing
MyoD with an artificially activated form of MEF2C.
Under these conditions, late muscle-gene expression can
be activated in replicating cells. Nevertheless, the preco-
cious activation of both the MCK reporter and endoge-
nous late muscle-differentiation markers is significantly
augmented by agents that block the cell cycle, such as
pRb or E2F1–pRb(SP). Together, these findings indicate
that high-level expression of late muscle-differentiation
markers requires both activation of MEF2 TAD function
as well as a G0 arrest, and argue that pRb plays an essen-
tial role during terminal muscle differentiation by regulat-
ing both of these processes (summarized in Figure 6).
It has been observed previously that ectopic expression of
either full-length E2F1 or the E2F1 DNA-binding
domain alone can potently inhibit the differentiation of
wild-type myoblasts [29–31], suggesting that suppression
of E2F activity may be a critical step in myogenic differ-
entiation. Here, we have found that an E2F1–pRb(SP)
chimeric protein that efficiently suppresses E2F-respon-
sive promoters and arrests cellular growth can only par-
tially substitute for pRb in driving the expression of either
a transfected MCK reporter or endogenous late muscle-
differentiation markers in Rb–/– fibroblasts. Thus, whereas
suppression of E2F activity and G0 arrest are normally
necessary for myogenesis, the cell-cycle-regulatory activi-
ties conveyed by the E2F1–pRb(SP) chimeric protein are
apparently not sufficient to promote complete myogenic
differentiation. This finding suggests that pRb may
contain a differentiation-promoting activity that is distinct
from its anti-proliferative functions. This idea is substanti-
ated by the finding that pRb mutants that are unable to
associate stably with E2F and are defective in cell-cycle
regulation are nevertheless able to stimulate cellular dif-
ferentiation programs [15]. Given our results, a second
muscle-differentiation-promoting activity of pRb can be
accounted for by the requirement for this factor to syner-
gistically activate the function of the MEF2C TAD in
combination with MyoD.
MyoD modulates MEF2 function through two independent
pathways
The finding that expression of MyoD induces the tran-
scriptional-activation function of the MEF2C TAD
reveals a novel mechanism by which MyoD may posi-
tively affect MEF2 activity and muscle-gene expression.
Previous work has suggested that synergism between
these two classes of transcription factors is mediated
through direct protein–protein contact between the
bHLH domain of MyoD and the MADS/MEF2 domain of
MEF2 [2,24,26]. Importantly, the ability of MyoD to acti-
vate MEF2C in our experiments did not require the
MADS/MEF2 domain, suggesting that MyoD can affect
MEF2 function without a need for direct protein binding.
Although our results cannot exclude the possibility that a
physical interaction between MyoD and MEF2 facilitates
the activation process, Olson and colleagues [32] have
recently demonstrated that an interaction between MyoD
and MEF2 can be uncoupled from MEF2 activation by
employing MyoD basic-region mutants that are unable to
functionally activate MEF2 yet can still physically interact
with it [32]. It is notable that these MyoD basic-region
mutants are also unable to establish the myogenic program
[33–35], raising the possibility that the ability of MyoD to
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Figure 6
MyoD and pRb synergistically activate the
function of the MEF2 TAD. MyoD can induce
expression of early muscle-differentiation-
specific genes such as myogenin, p21, and
MEF2 in the absence of pRb; pRb is then
required both to provide a permissive state for
MyoD to activate the function of the MEF2
TAD and to block E2F transcriptional activity.
pRb G0 growth arrest
MEF2 TAD
function
E2F
Current Biology  
MyoD
or
Myf-5
Myogenin
MEF2
p21
Late muscle-specific
gene expression
stimulate the MEF2 TAD may underlie the ability of
MyoD to recruit cells to the myogenic fate.
Substitution of the MEF2 TAD with that of VP16 pro-
duced an activated MEF2 protein that did not require
pRb for its function. When combined with MyoD,
MEF2C–VP16 was able to activate expression of late-
stage differentiation markers in cells lacking pRb. In con-
trast, a MyoD–VP16 chimeric protein, which could
strongly activate expression of a multimerized E-box
reporter construct in pRb-deficient cells, was unable to
activate expression of a MEF2 reporter construct or to
induce the expression of late-stage differentiation markers
without pRb (data not shown). These findings emphasize
the requirement for an activated TAD within MEF2 and
suggest that direct association of wild-type MEF2 with
MyoD–VP16 by a ‘piggy-back’ interaction [2,24] is not
sufficient either to convey transcriptional activity to
MEF2 or to induce late muscle-gene expression in the
absence of pRb.
Although it is currently unclear how MyoD activates the
function of the MEF2 TAD, our findings indicate that
this process requires both pRb and the Ser387 in the
MEF2 TAD. Given that phosphorylation of this serine by
MAP-kinase family members can increase the activity of
the MEF2 TAD [25,27], one possibility that we are cur-
rently investigating is that MyoD indirectly induces the
phosphorylation of this residue in a pRb-dependent
manner. Interestingly, the ectopic expression of the
broad-specificity MAP-kinase phosphatase MKP-1 has
recently been shown to interfere with the fusion of
myocytes into myotubes [36], a phenotype reminiscent of
the fusion defect seen in pRb-deficient myocytes [12]. It
is tempting to speculate that this effect may result from
the ability of the phosphatase to inhibit kinases that nor-
mally stimulate MEF2 TAD activity.
pRb controls entry into the later stages of the muscle
differentiation program
Myogenesis, like many other differentiation programs,
entails a coordination of cellular growth arrest and activation
of differentiation-specific gene expression. Here, we have
found that the coupling of these two processes is brought
about because they are regulated by the same protein, pRb.
In Rb–/– myocytes, genes that are normally induced in pro-
liferating cells within the first 24 hours of muscle differenti-
ation, such as myogenin and p21 [4], are expressed to levels
that are indistinguishable from those  of wild-type cells. In
contrast, genes that are expressed later in the differentiation
program and never normally observed in dividing cells are
either reduced or completely absent from cells lacking pRb
[10,12]. It is interesting to note that MyoD can activate the
expression of both myogenin and p21 in the absence of new
protein synthesis [37,38], suggesting that at least the initial
expression of these pRb-independent genes may occur
without the need for de novo MEF2 synthesis. In contrast,
analysis of the promoters of late muscle genes, such as
MCK and MRF-4, has indicated that an intact MEF2-
binding site, and therefore presumably MEF2 function, is
required for their expression (reviewed in [2,3,18]). Thus,
the absence of MEF2-dependent late-stage muscle-gene
expression in pRb-deficient skeletal muscle is completely
consistent with our findings that MEF2 transactivation
function is specifically defective in these cells, and may
explain why the expression of most muscle markers is nor-
mally confined to post-mitotic cells. These findings further
indicate that agents that modulate pRb function, such as
the G1 cyclins and Cdks, may act to control entry into the
later stages of myogenesis by modulating MEF2 activity
during normal embryonic development.
Materials and methods
Cell culture and transfection
Wild-type and Rb–/– mouse embryo fibroblasts isolated from day-13
embryos were kindly supplied by Tyler Jacks and cultured in medium
(DMEM) supplemented with 10% fetal bovine serum (FBS), as
described previously [10]. 10T½ fibroblasts were obtained from the
American Type Culture Collection and propagated in the same growth
medium. Fibroblasts were seeded at 1.5–1.75 × 105 cells per 60 mm
dish the day before transfection, and lipofected using 2–3 µg total
plasmid DNA and 10 µl Lipofectamine reagent (Life Technologies), as
described previously [10]. Myogenic differentiation was induced by
incubating the cells for 2–3 days in DMEM supplemented with 2%
horse serum and 10 µg/ml insulin. BrdU uptake experiments were per-
formed as previously described [10]. In these experiments, more than
80% of the differentiated myocytes incorporated BrdU. Differentiated
myocytes were identified by their weak expression of MHC.
Plasmids and reporter-gene assays
For transactivation experiments, 0.5 µg of the following cytomegalovirus
(CMV) expression plasmids were used: pCSA–MyoD [10];
pCSA–MyoD–VP16, created by subcloning a MyoD–VP16 fusion [35]
into the EcoRI site of pCSA; pCS2–MT6–MyoD (Myc-tagged MyoD
[39]); pCDNA1–MEF2C and pCDNA1–MEF2C(1–117)–VP16 [24];
pCDNA3–Gal4–MEF2C(TAD) constructs [25]; and pCS2–nuclear-β-
Gal, provided by R. Rupp and D. Turner. In some experiments, 0.1 µg
pCSA–E12 [39] was also included. These transactivators were com-
bined with 0.5 µg pCMV–pRb or 0.05–0.1 µg of either
pCMV–E2F1(1–368)–pRb(SP) or pCDNA1–HA–E2F1(1–368)–pRb(SP)
fusion protein constructs [15,28]. The amount of expression plasmids
encoding pRb and E2F1–pRb(SP) transfected in these experiments was
determined by titrating the amount of each plasmid and assaying for the
greatest effect on myogenesis. This amount corresponded to approxi-
mately two to three-fold greater expression of E2F1–pRb(SP) than pRb
as measured by protein immunoblotting (data not shown). All transfec-
tions contained 0.5 µg of one of the following reporter constructs:
MCK–luciferase, constructed by inserting the 3300 bp upstream
enhancer and promoter sequence from the mouse MCK gene [40] into
the plasmid pGL3–basic (Promega). Side-by-side comparisons indicate
that both MCK–CAT [40] and MCK–luciferase constructs have identical
promoter activities in both Rb–/– and 10T½ fibroblasts; E2F1-promoter
luciferase [15,28]; E-box reporter, 4R–TK–CAT [41]; MEF2-reporter,
MEF2x4–CAT [42]; Gal4–Luciferase, provided by A. Bonni and M.
Greenberg. CAT assays were performed as described previously [10],
and luciferase assays were performed using commercially available kits
(Analytical Luminescence Laboratories and Promega).
Viral infection, EMSA, and immunoblotting
Subconfluent wild-type and Rb–/– fibroblasts were infected with media
containing ecotropic MyoD virus from transfected BOSC 23 cells as
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described previously [10]. After 3 days’ culture under differentiation
conditions, whole-cell extracts were prepared and used for EMSA and
immunoblotting. The following antibodies were used: MyoD, mono-
clonal antibody 5.8A [43]; myogenin, monoclonal antibody F5D [44];
MHC, monoclonal antibody MF20 [45]; MCK, rabbit antiserum to
mouse MCK (kindly provided by Steve Hauschka) [22]; MEF2, affinity-
purified rabbit antibodies to MEF2 (C-21; Santa Cruz Biotechnology).
Note that the Santa Cruz MEF2C rabbit antibodies were generated
against human MEF2A, but they cross-react with both human and
mouse MEF2A, MEF2C, and MEF2D proteins (data not shown).
Immunostaining of myocytes
Cells were fixed and stained as described previously [10] using the fol-
lowing primary antibodies: Myc-tagged MyoD, monoclonal antibody
9E10; pRb, monoclonal antibody XZ-91 (Pharmingen); MEF2, affinity-
purified rabbit antibodies to MEF2 (C-21); CAT, affinity-purified rabbit
antibodies to CAT (5 Prime–3 Prime, Inc.); MHC, monoclonal antibody
MF20; MCK, rabbit antiserum to mouse MCK; BrdU, monoclonal anti-
body G3G4 (Developmental Studies Hybridoma Bank). Nuclei were
visualized by staining cells with 4',6'-diamidino-2-phenylindole (DAPI).
Cells were examined and photographed using a Zeiss Axioskop micro-
scope equipped with a 40× water-immersion objective.
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